BACKGROUND The coronary sinus (CS) Reducer is a recently introduced device to treat patients with severe anginal symptoms who are refractory to optimal medical therapy and not amenable for conventional revascularization. We aimed to assess the safety and efficacy of the CS Reducer in a "real world" cohort of patients with refractory angina.
BACKGROUND The coronary sinus (CS) Reducer is a recently introduced device to treat patients with severe anginal symptoms who are refractory to optimal medical therapy and not amenable for conventional revascularization. We aimed to assess the safety and efficacy of the CS Reducer in a "real world" cohort of patients with refractory angina.
METHODS This is a single center retrospective registry. Patients with severe anginal symptoms, objective evidence of myocardial ischemia using any modality and without options for conventional revascularization were regarded eligible for CS Reducer implantation.
RESULTS Twenty-three patients (74.0% male, mean age 70AE8 years) underwent CS Reducer implantation (91.0% previous bypass surgery, 48.0% previous myocardial infarction, 83.0% previous percutaneous intervention, 52.0% diabetes mellitus). The safety endpoint (successful delivery and deployment) was met in all patients. One patient suffered a procedure-related access site complication (neck hematoma), which was treated conservatively. After a median follow-up of 9 [8] [9] [10] [11] [12] [13] [14] months the efficacy endpoint (any reduction in Canadian Cardiovascular Society (CCS) class with revascularization free survival) was reached in 17 patients (74.0%). The majority of patients (78.3%) experienced an improvement of clinical symptoms: 8 (34.8%) by 1 CCS class, 8 (34.8%) by 2 CCS classes (1 of them underwent a revascularization at follow up) and 2 (8.7%) by 3 CCS classes. One patient died 4 month after implantation because of progressive heart failure (no association with the CS Reducer implantation).
CONCLUSIONS In this single center 'real-world' experience, the CS Reducer implantation was safe and demonstrated clinical efficacy in the treatment of refractory angina at mid-term follow-up. BACKGROUND Although fractional flow reserve (FFR) is the gold standard in functional assessment of intermediate coronary stenosis, it lacks anatomical information essential for risk stratification of plaque and guidance of PCI. In IVUS, integrated backscatter (IB) values of blood speckles, calculated as the average power of backscattered radiofrequency (RF) signals from blood, have been shown to change as a function of blood flow velocity. This study aimed to investigate potential utility of RF-IVUS for assessment of functional significance of intermediate coronary stenosis.
METHODS In 42 patients with intermediate lesions in !1 epicardial coronary arteries, 45 arteries (28 left anterior descending; 3 left circumflex; 14 right coronary artery) were evaluated by IB-IVUS and intracoronary pressure measurements. Average IB values of blood speckles within the lumen were measured at proximal (a segment near the orifice of the artery) and distal (a disease-free segment >10 mm distal to the tightest site) segments to the lesion. As IB is a logarithmic variable, a ratio of the distal and proximal IB values was calculated as DIB between the 2 sites. As control, FFR during hyperemia and instantaneous wave-free ratio (iFR) were obtained using a coronary pressure wire.
RESULTS Overall, the minimum lumen area (MLA) of the lesions ranged from 1.0 to 7.4 mm2 (median 2.1 mm2). DIB significantly correlated with both FFR and iFR (Figure) , which was also confirmed in a subset of lesions with small MLA (defined as < the median value). Receiver operating characteristic (ROC) curve analyses identified the best cut-off value as 7.25 of DIB for predicting FFR 0.8 (sensitivity 100%; specificity 88%; positive predictive value 86%; negative predictive value 100%, accuracy 93%), and 9.14 of DIB for predicting iFR 0.89 (sensitivity 100%; specificity 79%; positive predictive value 61%; negative predictive value 100%; accuracy 84%).
CONCLUSIONS This study supports the feasibility of RF-IVUS to estimate coronary physiology across intermediate stenosis, demonstrating significant association of blood DIB with FFR and iFR even in relatively small MLA lesions. Further investigation is warranted to confirm the potential utility of RF-IVUS for hybrid (both anatomic and functional) assessment of coronary artery disease, which may be helpful for time and cost-effective resource utilization. BACKGROUND To determine the specific cause of death and their potential influencing factors in patients with complex coronary artery disease who underwent percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG) in the SYNTAX randomized trial and nested registries.
METHODS An independent Clinical Events Committee consisting of expert physicians blinded to the study treatment, sub-classified causes of death in cardiovascular (cardiac and vascular), non-cardiovascular and undetermined according to the trial protocol. Cardiac deaths were classified as sudden cardiac, myocardial infarction (MI)-related and other cardiac deaths. Multivariate models were constructed to identify independent predictors of all-cause and cardiac death after PCI and CABG.
RESULTS
In the randomized cohort, during 5-year follow-up, there were 123 deaths after PCI and 97 deaths after CABG. After PCI, the majority of deaths were cardiovascular (67.5%) and as a result of MI (29.3%), whereas after CABG 49.4% of deaths were cardiovascular with the largest cause being heart failure, arrhythmia or other causes (24.6%). The cumulative incidence rates of all-cause death were not significantly different between CABG and PCI (11.4 vs. 13.9%, respectively; P¼0.10), while there were significant differences in terms of cardiovascular (5.8 vs. 9.6%, respectively; P¼0.008) and cardiac (5.3 vs. 9.0%, respectively; P¼0.003) death, caused primarily by a reduction in MI-related death with CABG as compared with PCI (0.4 vs. 4.1%, respectively; P<0.0001). The difference in MI-related death was seen largely in patients with diabetes, three-vessel disease, or high SYNTAX scores. Independent predictors of all-cause and cardiac death consisted of baseline, procedural and post-procedural variables, with important predictors being discharge medication use and adverse events during followup. Results for the nested registries were similar, although the death rate in the PCI registry was higher and more often the result of non-cardiovascular causes.
CONCLUSIONS The rate of all-cause death at 5 years was not significantly different between PCI and CABG. However, CABG in comparison with PCI was associated with a significantly reduced rate of MIrelated death, which was the leading cause of death after PCI, particularly in patients with complex disease and in the presence of diabetes. BACKGROUND In the past two decades, significant advances have occurred in the management of coronary artery disease. It is unclear whether increased options for treatment, improved technology and expanded available evidence have translated into nationwide changes in comorbidity profiles and outcomes of patients presenting for PCI.
METHODS 3,387,976 Medicare beneficiaries >¼ 65 yrs of age who underwent PCI from 1/2000 -11/2012 were included. Comorbidities were determined using ICD-9-CM diagnostic codes from any hospitalization within 1 yr prior to index admission. Trends in patient characteristics and hospital outcomes were assessed with Cochran-Armitage trend tests. Long-term survival was examined with Kaplan-Meier survival curves.
